Scientific Perspectives
Jul 24, 2026
Turning Cold Tumors Hot: The Mechanistic Case for IL-12 and IL-18 Combinations in Microenvironment Remodeling
Most immunotherapy failures in solid tumors trace back to a single root problem: the tumor microenvironment was never sufficiently infiltrated in the first place. Checkpoint inhibitors that block PD-1 or CTLA-4 depend on pre-existing cytotoxic T-cell infiltration to generate a response, and in immunologically cold or excluded tumors, that infiltration is absent. Solving cold tumor conversion is therefore not an incremental improvement over existing immunotherapy; it is a prerequisite for expanding the population of patients who can benefit from it at all.
The Biology of Cold Tumor Conversion: Why IL-12 and IL-18 Are a Logical Pair
Cold tumors are defined not simply by the absence of T cells, but by an immune contexture that actively suppresses type 1 inflammatory signaling. Restoring that signaling requires cytokines capable of initiating and sustaining a Th1-dominant response, and two of the most biologically potent candidates are IL-12 and IL-18.
IL-12 is a central activator of cytotoxic T lymphocytes and NK cells, drives IFN-γ production, and enhances antigen presentation within the tumor microenvironment. Critically, preclinical studies of engineered IL-12 formats have shown that localized delivery can reshape the immune contexture from cold to hot while reducing the systemic inflammatory toxicity that historically limited clinical translation of native IL-12.
IL-18 operates through a complementary but distinct mechanism. It amplifies IFN-γ production in T cells and NK cells primed by other stimuli and supports the sustained effector activity needed to maintain an inflamed microenvironment rather than simply initiating it. The relationship between these two cytokines is not merely additive: evidence from engineered T-cell models indicates that IL-12 upregulates IL-18R1 expression on T cells, creating a feed-forward axis in which IL-12 priming increases the functional responsiveness of infiltrating lymphocytes to subsequent IL-18 signaling. In this context, cold tumor conversion may require both a priming signal and an amplification signal rather than a single cytokine alone.
Dendritic-cell vaccine studies combining IL-12 and IL-18 have demonstrated increased CD4+ and CD8+ T-cell infiltration into tumors and tumor-draining lymph nodes relative to either cytokine alone, consistent with a shift toward an inflamed rather than immune-desert state. Even a single administration was sufficient to trigger systemic anti-tumor effects in murine models, reinforcing the hypothesis that properly delivered dual-cytokine signaling can drive durable microenvironmental reprogramming.
Why Delivery Engineering Determines Therapeutic Index
The historical failure of IL-12 in early clinical trials was not a failure of biology. It was a failure of delivery. Systemic administration produced dose-limiting toxicity before adequate intratumoral concentrations could be achieved, and the same dynamic threatens to constrain IL-18-based approaches, compounded further by IL-18 binding protein (IL-18BP), an endogenous decoy receptor enriched in the tumor microenvironment that can sequester IL-18 and blunt its activity before it reaches effector cells. Engineering strategies designed to overcome IL-18BP-mediated neutralization have become a central design principle for next-generation IL-18 therapeutics. Guidant's IL-18 is novel and patent-protected. Unlike wildtype IL-18, Guidant's IL-18 variant does not bind IL-18 Binding Protein, thereby avoiding the negative feedback regulation associated with elevated IL-18BP levels entirely.
For any dual-cytokine format to achieve cold tumor conversion at clinically acceptable doses, intratumoral exposure must be maximized while peripheral cytokine levels are controlled. This is precisely the pharmacokinetic challenge that platform-level delivery innovation is positioned to address. Guidant's FHAB (Fully Human Albumin-Binding) navigated delivery platform exploits the body's natural albumin biology to achieve this kinetic control. Human serum albumin accumulates preferentially in tumors and inflamed tissues through FcRn receptor recycling, providing a physiologically grounded mechanism for concentrating therapeutic payloads in the compartment where they are most needed while extending circulating half-life by up to 10-fold relative to unmodified cytokines.
For a dual-cytokine concept like IL-12 plus IL-18, this matters not only for tolerability but for mechanism. The feed-forward relationship between these two cytokines, in which IL-12 sensitizes infiltrating T cells to IL-18 signaling, depends on both cytokines being present at sufficient concentrations in the same immune compartment. Systemic distribution undermines this spatial co-localization; tumor-enriched delivery preserves it.
GDT-003: A First-in-Class Dual Cytokine Candidate Built on the FHAB Platform
Guidant's preclinical candidate GDT-003 (IL18-FHAB-IL12) is designed to address this convergence of biological rationale and delivery constraint. As a first-in-class IL-12 plus IL-18 dual cytokine formatted as a fusion protein on the FHAB platform, GDT-003 is intended to co-deliver both cytokines in an albumin-bound format that leverages tumor-preferential accumulation, with issued intellectual property supporting the approach. The candidate is in preclinical development for solid tumors, and the mechanistic premise is grounded in the same priming-plus-amplification logic described above.
This positions GDT-003 as a potential upstream enabler for combination strategies. Tumors converted from cold to hot through IL-12 and IL-18 driven IFN-γ induction, myeloid reprogramming, and cytotoxic T-cell recruitment become more likely to respond to checkpoint inhibitors, which require pre-existing immune infiltration to function. The same logic applies to combination with antibody-drug conjugates that trigger immunogenic cell death: cytokine-mediated priming could help ensure that antigen released by ADC payloads generates a productive adaptive immune response rather than an immunologically silent bystander effect. Guidant's broader oncology pipeline reflects this integrated thinking, pairing cytokine engineering with a dual-payload ADC program designed for the same goal of improved intratumoral activity with better systemic tolerability.
Biomarker strategy will be critical for translating this biology into clinical development. For IL-18-based programs, IL-18BP levels in the tumor microenvironment represent an obvious pharmacodynamic and patient-selection variable. For IL-12, established readouts include IFN-γ signatures, CXCL9 and CXCL10 induction, CD8+ T-cell infiltration density, and evidence of myeloid reprogramming. Emerging data on cytokine-based tumor remodeling continue to refine which combinations of these markers most reliably predict durable immune activation rather than transient inflammation.
Implications for the Field and Guidant's Development Path
Cold tumor conversion through dual IL-12 and IL-18 signaling is one of the most mechanistically coherent strategies in immuno-oncology, and the preclinical evidence supports both its rationale and its delivery dependence. The question for clinical translation is whether tumor-enriched cytokine exposure can produce durable immune remodeling at doses that preserve tolerability. Albumin-mediated delivery is a scientifically grounded answer to that question, one that Guidant's navigated delivery platform is designed to test in a rigorous, biomarker-guided development framework.
Explore the mechanistic foundation of the FHAB platform and its application across Guidant's cytokine and ADC programs on the Technology page.